PBAC's latest decision on Triptorelin acetate: Recommended with restriction (2016). Considered for Down-regulation and prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) as part of an Assisted Reproductive Technology (ART) treatment program.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2016
Submissions
1
2016 → 2016
Eligible population
Women undergoing controlled ovarian hyperstimulation as part of an Assisted Reproductive Technology (ART) treatment program requiring prevention of premature luteinisation and ovulation.
Therapy area
Women's health
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Ongoing pregnancy rate
Pivotal trial size
559 patients
Key trials
EMEOSG 2001, Rombauts 2006
Comparator
nafarelin
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.